)
Visual
test
Artiva Biotherapeutics
Artiva Biotherapeutics (ARTV) investor relations material
Artiva Biotherapeutics Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary10 Mar, 2026
Executive summary
Advanced AlloNK program, prioritizing refractory rheumatoid arthritis (RA) as lead indication and enrolling patients in community settings.
Received FDA Fast Track designation for AlloNK in refractory RA and established strong outpatient feasibility and safety profile.
Strengthened executive and board leadership with expertise in immunology, commercial, and financial strategy.
Financial highlights
Cash, cash equivalents, and investments totaled $108.0 million as of December 31, 2025, expected to fund operations into Q2 2027.
Research and development expenses were $69.5 million for 2025, up from $50.3 million in 2024.
General and administrative expenses were $20.3 million for 2025, compared to $17.2 million in 2024.
Net loss was $83.9 million for 2025, compared to $65.4 million in 2024.
License and development support revenue was zero for 2025, down from $0.3 million in 2024.
Outlook and guidance
Initial clinical response data for AlloNK in refractory RA expected in the first half of 2026 from at least 15 patients.
Planned FDA interaction in the first half of 2026 to discuss potential pivotal trial design for AlloNK in refractory RA.
Cash runway expected to fund operations into Q2 2027.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Artiva Biotherapeutics
- Lead focus on refractory RA with scalable, safe NK cell therapy aiming for first-to-market entry.ARTV
TD Cowen 46th Annual Health Care Conference4 Mar 2026 - NK cell therapy targets autoimmune diseases with outpatient potential and key data due next year.ARTVJefferies London Healthcare Conference 202413 Jan 2026
- Scalable NK cell therapy shows promise for safe, community-based autoimmune treatment.ARTV24th Annual Needham Virtual Healthcare Conference23 Dec 2025
- AlloNK's Phase I autoimmune trials leverage strong NHL data and offer outpatient, scalable therapy.ARTVTD Cowen 45th Annual Healthcare Conference17 Dec 2025
- Biotech seeks up to $300M for NK cell therapy trials, with $11.95M ATM via Leerink Partners.ARTVRegistration Filing16 Dec 2025
- Proxy seeks approval for director election, auditor ratification, and equity plan amendment.ARTVProxy Filing2 Dec 2025
- Vote on director election, auditor ratification, and equity plan share increase at annual meeting.ARTVProxy Filing2 Dec 2025
- IPO seeks $117M to advance off-the-shelf NK cell therapies for autoimmune diseases and cancer.ARTVRegistration Filing30 Nov 2025
- IPO aims to fund scalable NK cell therapies for autoimmune disease; early data expected 2025.ARTVRegistration Filing29 Nov 2025
Next Artiva Biotherapeutics earnings date
Q1 202613 May, 2026
Artiva Biotherapeutics
Next Artiva Biotherapeutics earnings date
Q1 202613 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage